《医学前沿（英文）》
>> 2021年
第15卷
第1期
doi:
10.1007/s11684-020-0741-5
REVIEW
Progress in systemic therapy for triple-negative breast cancer
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
收稿日期：
2020-04-19
录用日期：
2020-08-12
发布日期：
2020-08-12
下一篇
上一篇
摘要
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with a heterogeneous genetic profile. Chemotherapy exhibits substantial activity in a small subset of these patients. Drug resistance is inevitable. Major progress has been made in the genetic analysis of TNBC to identify novel targets and increase the precision of therapeutic intervention. Such progress has translated into major advances in treatment strategies, including modified chemotherapy approaches, immune checkpoint inhibitors, and targeted therapeutic drugs. All of these strategies have been evaluated in clinical trials. Nevertheless, patient selection remains a considerable challenge in clinical practice.
京公网安备 11010502051620号
